Zobrazeno 1 - 10 of 76 pro vyhledávání: '"We, Fogler"'
1
IL-7 activates alpha4beta1 integrin in murine thymocytes
Autor: Kitazawa H, Muegge K, Badolato R, Jm, Wang, We, Fogler, Dk, Ferris, Ck, Lee, Candéias S, Smith MR, Jj, Oppenheim, scott durum
Publikováno v: Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 1997, 159 (5), pp.2259-64
Journal of Immunology, 1997, 159 (5), pp.2259-64
Europe PubMed Central
IL-7, a cytokine produced by thymic epithelium, was shown to induce adhesion of murine thymocytes to gelatin-coated membranes. A major binding component of gelatin was identified as fibronectin. IL-7-induced adhesion was observed for all of the major
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9866c90172391cc3b634add6d29c4686
https://doi.org/10.4049/jimmunol.159.5.2259
Zobrazit plný text záznamu
2
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer
Autor: Andrew Feldman, Tamarkin L, Gf, Paciotti, Bw, Simpson, Wm, Linehan, Jc, Yang, We, Fogler, Em, Turner, Hr, Alexander, Sk, Libutti
Publikováno v: Europe PubMed Central
Clear cell renal carcinoma (CCRC) is a highly angiogenic tumor known to secrete vascular endothelial cell growth factor (VEGF). Endostatin is an endogenous antiangiogenic agent with antitumor activity in mice. The purpose of this study was to evaluat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::19ad7d8b8680d750435eadee9b76cc31
https://pubmed.ncbi.nlm.nih.gov/11156212
Zobrazit plný text záznamu
3
Differential tyrosine phosphorylation of inhibitory versus activating Ly-49 receptor proteins and their recruitment of SHP-1 phosphatase
Autor: Lh, Mason, Gosselin P, Sk, Anderson, We, Fogler, Jr, Ortaldo, Daniel McVicar
Publikováno v: Europe PubMed Central
Killer cell inhibitory receptors represent a family of p58/70-Ig-like proteins expressed on the surface of human NK cells. Engagement of class I MHC by killer cell inhibitory receptors turns off the lytic machinery of NK cells. This receptor/ligand i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7e4abccd9a225f566c56a8e95530f896
http://europepmc.org/abstract/med/9379012
Zobrazit plný text záznamu
4
Akademický článek
Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia.
Autor: Enjeti AK; Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia.; NSW Health Pathology, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.; Precision Medicine Program, Hunter Medical Research Institute and University of Newcastle, New Lambton Heights, New South Wales, Australia.; University of Newcastle, Callagan, NSW, Australia., Fogler WE; GlycoMimetics, Inc., Rockville, Maryland, USA., Smith TAG; GlycoMimetics, Inc., Rockville, Maryland, USA., Lincz LF; Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia.; University of Newcastle, Callagan, NSW, Australia., Bond DR; Precision Medicine Program, Hunter Medical Research Institute and University of Newcastle, New Lambton Heights, New South Wales, Australia.; University of Newcastle, Callagan, NSW, Australia., Magnani JL; GlycoMimetics, Inc., Rockville, Maryland, USA.
Publikováno v: British journal of haematology [Br J Haematol] 2024 Jun; Vol. 204 (6), pp. 2264-2274. Date of Electronic Publication: 2024 Apr 24.
Zobrazit plný text záznamu
5
Report
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Autor: Jia Y; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Zhang W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Basyal M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang KH; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ostermann L; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burks JK; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ly C; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mu-Mosley H; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang Q; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Han X; Department of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fogler WE; GlycoMimetics, Inc., Rockville, MD, USA., Magnani JL; GlycoMimetics, Inc., Rockville, MD, USA., Lesegretain A; Daiichi Sankyo, Inc., Basking Ridge, NJ, USA., Zal AA; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zal T; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.
Publikováno v: Leukemia [Leukemia] 2023 Jun; Vol. 37 (6), pp. 1379-1383. Date of Electronic Publication: 2023 Apr 21.
Zobrazit plný text záznamu
6
Akademický článek
E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis.
Autor: Myers DD Jr; Conrad Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich; Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, Mich. Electronic address: ddmyers@umich.edu., Ning J; Department of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Lester P; Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, Mich., Adili R; Department of Pharmacology, University of Michigan, Ann Arbor, Mich., Hawley A; Conrad Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich., Durham L; Conrad Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich., Dunivant V; Conrad Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich., Reynolds G; Conrad Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich., Crego K; Conrad Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich., Sood S; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich., Sigler R; Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, Mich., Fogler WE; GlycoMimetics, Inc., Gaithersburg, Md., Magnani JL; GlycoMimetics, Inc., Gaithersburg, Md., Holinstat M; Department of Pharmacology, University of Michigan, Ann Arbor, Mich., Wakefield T; Conrad Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich.
Publikováno v: Journal of vascular surgery. Venous and lymphatic disorders [J Vasc Surg Venous Lymphat Disord] 2022 Jan; Vol. 10 (1), pp. 211-220. Date of Electronic Publication: 2021 Apr 17.
Zobrazit plný text záznamu
7
Report
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy.
Autor: Muz B; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Azab F; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Fiala M; Department of Medicine, Division of Medical Oncology, Washington University in St. Louis School of Medicine, Saint Louis, MO, USA., King J; Department of Medicine, Division of Medical Oncology, Washington University in St. Louis School of Medicine, Saint Louis, MO, USA., Kohnen D; Department of Medicine, Division of Medical Oncology, Washington University in St. Louis School of Medicine, Saint Louis, MO, USA., Fogler WE; GlycoMimetics Inc., Rockville, MD, USA., Smith T; GlycoMimetics Inc., Rockville, MD, USA., Magnani JL; GlycoMimetics Inc., Rockville, MD, USA., Vij R; Department of Medicine, Division of Medical Oncology, Washington University in St. Louis School of Medicine, Saint Louis, MO, USA., Azab AK; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA. kareem.azab@wustl.edu.
Publikováno v: Blood cancer journal [Blood Cancer J] 2019 Aug 20; Vol. 9 (9), pp. 68. Date of Electronic Publication: 2019 Aug 20.
Zobrazit plný text záznamu
8
Akademický článek
P- and E-selectin receptor antagonism prevents human leukocyte adhesion to activated porcine endothelial monolayers and attenuates porcine endothelial damage.
Autor: Laird CT; University of Maryland SOM, Baltimore, MD, USA., Hassanein W; University of Maryland SOM, Baltimore, MD, USA., O'Neill NA; University of Maryland SOM, Baltimore, MD, USA., French BM; University of Maryland SOM, Baltimore, MD, USA., Cheng X; University of Maryland SOM, Baltimore, MD, USA., Fogler WE; GlycoMimetics, Inc, Rockville, MD, USA., Magnani JL; GlycoMimetics, Inc, Rockville, MD, USA., Parsell D; University of Maryland SOM, Baltimore, MD, USA., Cimeno A; University of Maryland SOM, Baltimore, MD, USA., Phelps CJ; Revivicor, Inc, Blacksburg, VA, USA., Ayares D; Revivicor, Inc, Blacksburg, VA, USA., Burdorf L; University of Maryland SOM, Baltimore, MD, USA., Azimzadeh AM; University of Maryland SOM, Baltimore, MD, USA., Pierson RN 3rd; University of Maryland SOM, Baltimore, MD, USA.; GlycoMimetics, Inc, Rockville, MD, USA.
Publikováno v: Xenotransplantation [Xenotransplantation] 2018 Mar; Vol. 25 (2), pp. e12381. Date of Electronic Publication: 2018 Jan 23.
Zobrazit plný text záznamu
9
Akademický článek
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.
Autor: Natoni A; Apoptosis Research Centre, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland., Smith TAG; GlycoMimetics, Inc., Rockville, MD, USA., Keane N; Apoptosis Research Centre, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland.; Department of Hematology, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland., McEllistrim C; Department of Hematology, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland., Connolly C; Apoptosis Research Centre, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland.; Department of Hematology, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland., Jha A; Insight Centre for Data Analytics, National University of Ireland Galway, Galway, Ireland., Andrulis M; Institute of Pathology, University of Ulm, Ulm, Germany.; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Ellert E; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Raab MS; Experimental Therapeutics for Hematologic Malignancies German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine V, Heidelberg University Medical Center, Heidelberg, Germany., Glavey SV; Apoptosis Research Centre, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland.; Department of Hematology, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland., Kirkham-McCarthy L; Apoptosis Research Centre, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Locatelli-Hoops SC; GlycoMimetics, Inc., Rockville, MD, USA., Oliva I; GlycoMimetics, Inc., Rockville, MD, USA., Fogler WE; GlycoMimetics, Inc., Rockville, MD, USA., Magnani JL; GlycoMimetics, Inc., Rockville, MD, USA., O'Dwyer ME; Apoptosis Research Centre, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland.; Department of Hematology, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland.
Publikováno v: Leukemia [Leukemia] 2017 Dec; Vol. 31 (12), pp. 2642-2651. Date of Electronic Publication: 2017 Apr 25.
Zobrazit plný text záznamu
10
Akademický článek
ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
Autor: Fletcher GC; Entremed Inc., 101 College Street, Toronto, Ontario, Canada M5G 1L7., Brokx RD, Denny TA, Hembrough TA, Plum SM, Fogler WE, Sidor CF, Bray MR
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2011 Jan; Vol. 10 (1), pp. 126-37. Date of Electronic Publication: 2010 Dec 21.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje